T1	Cluster1 26 71	human induced pluripotent stem cells (hiPSCs)
T2	Cluster1 738 748	The hiPSCs
T3	Cluster1 474 480	hiPSCs
T4	Cluster1 1272 1278	hiPSCs
T5	Entity 241 256	hiPSC expansion
T6	Entity 455 473	efficiently expand
T7	Entity 211 236	a scalable culture system
T8	Cluster3 1128 1139	This system
T9	Cluster4 605 618	the E8 medium
T10	Cluster4 1414 1423	E8 medium
T11	Cluster4 263 309	the E8 chemically defined and xeno-free medium
T12	Entity 1199 1229	completely xeno-free condition
T13	Entity 1542 1581	completely defined xeno-free conditions
T14	Cluster6 1163 1195	an efficient scale-up bioprocess
T15	Cluster6 1720 1734	the bioprocess
T16	Cluster6 1517 1538	a scalable bioprocess
T17	Cluster7 1598 1628	a single-cell cryopreservation
T18	Cluster7 1029 1057	single-cell cryopreservation
T19	Entity 144 169	translational realization
T20	Entity 199 210	demonstrate
T21	Entity 370 391	suspension conditions
T22	Entity 402 428	a computational simulation
T23	Entity 531 547	Serial passaging
T24	Entity 656 666	expression
T25	Entity 629 651	their normal karyotype
T26	Entity 619 628	preserved
T27	Entity 761 775	spinner flasks
T28	Entity 749 757	cultured
T29	Entity 829 840	pluripotent
T30	Entity 1005 1025	a xeno-free protocol
T31	Entity 1062 1070	recovery
T32	Entity 1075 1098	the scalable production
T33	Entity 1323 1344	clinical applications
T34	Entity 1437 1465	the first hydrodynamic model
T35	Entity 1470 1500	glass-ball type spinner flasks
T36	Cluster1 1657 1668	Human iPSCs
T37	Entity 1588 1597	optimized
T38	Entity 0 22	Large-scale production
T39	Entity 75 102	robust and economic methods
T40	Entity 173 189	hiPSC technology
T41	Entity 484 529	undifferentiated aggregates in spinner flasks
T42	Cluster9 551 598	two different hiPSC lines in the spinner flasks
T43	Entity 670 700	undifferentiated state markers
T44	Entity 931 975	mesodermal and hematopoietic differentiation
T45	Entity 1102 1126	hiPSCs in spinner flasks
T46	Entity 1284 1308	the quantity and quality
T47	Entity 1369 1407	the first suspension culture of hiPSCs
T48	Entity 1633 1653	hiPSCs in suspension
T49	Entity 1680 1713	pluripotency and normal karyotype
T50	Entity 857 884	in vitro and in vivo assays
T51	Entity 1234 1268	the expansion and cryopreservation
T52	Entity 316 356	either adherent or suspension conditions
T53	Entity 361 369	optimize
T54	Entity 704 712	TRA-1-60
T55	Entity 714 719	SSEA4
T56	Entity 721 725	OCT4
T57	Entity 731 736	NANOG
T58	Entity 790 792	10
T59	Entity 793 801	passages
T60	Entity 904 923	efficiently induced
T61	Entity 1669 1679	maintained
T62	Cluster8 196 198	we
T63	Cluster8 1359 1361	We
T64	Cluster8 1427 1429	We
T65	Cluster8 1504 1506	We
T66	Cluster8 1585 1587	We
T67	Cluster8 430 432	we
T68	Cluster9 629 634	their
T69	Cluster8 990 992	we
T70	Cluster3 211 256	a scalable culture system for hiPSC expansion
